1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

• Source: Scrip

Iovance Biotherapeutics, Inc.’s tumor-infiltrating lymphocyte (TIL) Amtagvi (lifileucel) scored a win in February as the first cell therapy to win US Food and Drug Administration approval for a solid tumor indication. In the years ahead, more TIL, T-cell receptor (TCR) and chimeric antigen receptor T-cell (CAR-T) therapies will likely hit the market. But while it appears the age of cell therapy for solid tumors has finally arrived, each modality faces unique challenges not associated with CAR-T therapies approved for blood cancers.

Next-generation cell therapies, including Amtagvi, were the topic of a 2 June educational session at the recent American

Key Takeaways

  • With Amtagvi’s approval, and Adaptimmune’s afami-cel on its way to the finish line, cell therapies for solid tumors are finally becoming a reality.

  • While CAR-Ts in blood cancers have been relatively straightforward in terms of targetable antigens and high response rates, they face a number of challenges in solid tumors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from Bio-Europe

Norway’s Nykode Eyes NASDAQ As Pipeline Advances

 
• By Kevin Grogan

CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.

Novartis Casts Nets Globally To Snap Up Best Assets

 
• By Kevin Grogan

The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.